Author

Roger Crystal

Institution: Indivior (United States)

Observed institutions: National Institutes of Health, National Institute on Drug Abuse, The Royal Free Hospital, Indivior (United States)

ORCID: 0000-0002-7190-9970

Observed ORCID: 0000-0002-7190-9970

OpenAlex ID: A5034900701

Pharmacokinetic Properties and Human Use Characteristics of an FDA‐Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose

2016 · Philip Krieter, Nora Chiang, et al. · The Journal of Clinical Pharmacology · 111

Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects

2019 · Jarkko Johansson, Jussi Hirvonen, et al. · Neuropsychopharmacology · 57

Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose

2019 · Philip Krieter, Shwe Gyaw, et al. · Journal of Pharmacology and Experimental Therapeutics · 55

Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose

2023 · Roger Crystal, Mark Ellison, et al. · Clinical Pharmacology in Drug Development · 31

Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose

2019 · Philip Krieter, Shwe Gyaw, et al. · The Journal of Clinical Pharmacology · 18

Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose

2019 · Phil Skolnick, Roger Crystal · Journal of Neural Transmission · 9

Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes

2019 · Sari Castrén, Niklas Mäkelä, et al. · BMJ Open · 6

Ambulance alerting of paediatric emergencies to a general hospital

2004 · Roger Crystal, Anthony Bleetman · Resuscitation · 3

Works count: 8

Citation count: 290

H-index: 6

I10-index: 5